Toregem Bio Raises $5.3 Million for TRG-035 Tooth-Regrowing Trials as Backing Tops $29 Million
Updated
Updated · The Economic Times · May 30
Toregem Bio Raises $5.3 Million for TRG-035 Tooth-Regrowing Trials as Backing Tops $29 Million
1 articles · Updated · The Economic Times · May 30
Summary
$5.3 million in Pre-Series C funding will help Toregem Bio advance human trials of TRG-035, pushing total support for the Kyoto-based company beyond $29 million.
TRG-035 blocks the USAG-1 protein, which researchers believe keeps dormant tooth buds inactive; removing that brake could trigger a new round of tooth development.
A Phase I study at Kyoto University Hospital enrolled 30 healthy men aged 30 to 64 missing at least one molar to test safety before later-stage trials.
Toregem is first targeting congenital tooth agenesis in children, where implants and dentures can be difficult while jaws are still developing.
Human tooth regrowth remains unproven: recruitment for the Phase I trial had ended by March 2026, but peer-reviewed results have not yet been published and experts say implants remain the standard treatment.
With the first human safety trial now finished, did this revolutionary drug successfully regenerate any teeth in participants?
Could this tooth-regrowing medicine truly make dental implants and dentures a thing of the past within this decade?
By reactivating dormant tooth buds, what are the hidden long-term risks of manipulating these powerful biological growth pathways?
TRG-035 Antibody Therapy: Transforming Tooth Loss Treatment with Regeneration—Clinical, Commercial, and Global Perspectives
Overview
Toregem BioPharma, a spin-out from Kyoto University, is developing TRG-035, an innovative antibody medicine designed to regenerate teeth by targeting the USAG-1 protein, which normally suppresses new tooth growth after adult teeth emerge. By inhibiting USAG-1, TRG-035 aims to reactivate the body’s natural ability to grow new teeth, offering a breakthrough in dental treatment. While this approach has opened real possibilities for biological tooth regeneration, as of May 2026, there is no public information on the completion of Phase I clinical trials or recent funding, highlighting the need for further research and data before widespread use.